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The Pediatric Sepsis Biomarker Risk 
Model (PERSEVERE) Biomarkers 
Predict Clinical Deterioration and 
Mortality in Immunocompromised 
Children Evaluated for Infection
L. Jacobs  1, Z. Berrens  2, E. K. Stenson3, M. W. Zackoff3, L. A. Danziger4, P. Lahni3 & 
H. R. Wong3
Pediatric sepsis and bacterial infection cause significant morbidity and mortality worldwide, with 
immunocompromised patients being at particularly high risk of rapid deterioration and death. This 
study evaluated if PERSEVERE, PERSEVERE-II, or the PERSEVERE biomarkers, can reliably estimate 
the risk of clinical deterioration and 28-day mortality among immunocompromised pediatric patients. 
This is a single-center prospective cohort study conducted from July 2016 through September 2017 
incorporating 400 episodes of suspected bacterial infection from the inpatient units at Cincinnati 
Children’s Hospital Medical Center, a large, tertiary care children’s hospital. The primary analysis 
assessed clinical deterioration within 72 hours of evaluation for infection. Secondarily, we assessed 
28-day mortality. Clinical deterioration was seen in 15% of subjects. Twenty-eight day mortality was 
5%, but significantly higher among critically ill patients. Neither PERSEVERE nor PERSEVERE-II 
performed well to predict clinical deterioration or 28-day mortality, thus we derived new stratification 
models using the PERSEVERE biomarkers with both high sensitivity and negative predictive value. In 
conclusion, we evaluated previously validated biomarker risk models in a novel population of largely 
non-critically ill immunocompromised pediatric patients, and attempted to stratify patients based 
on a new outcome metric, clinical deterioration. The new highly predictive models indicate common 
physiologic pathways to clinical deterioration or death from bacterial infection.
Sepsis remains a significant health issue worldwide, contributing to substantial morbidity and mortality among 
pediatric patients. Recent literature suggests an 8% point prevalence of pediatric severe sepsis, with an associated 
25% in-hospital mortality rate1. Immunocompromised pediatric patients are at even higher risk of infection and 
subsequent deterioration, with mortality approaching 40–50%1. A 2015 epidemiologic study evaluating the inci-
dence of infection among bone marrow transplant recipients indicated that almost half (46%) of patients have 
a documented infection during a hospital stay, with mortality rates doubling once a patient becomes infected2.
This burden has pushed researchers to seek a better understanding of individual patients’ phenotypes and 
risk of decompensation. Acquisition of patient-specific knowledge allows clinicians to identify patients at high 
risk of deterioration, better focus resources, and provide targeted therapies. The Pediatric Sepsis Biomarker Risk 
Model (PERSEVERE)3 is a biomarker-based stratification tool to estimate a specific patient’s baseline risk of mor-
tality from sepsis. Using genome-wide expression profiling, Wong et al. identified twelve candidate prognostic 
biomarkers in critically ill septic pediatric patients4–7. The twelve biomarkers were pared down to five having the 
highest predictive capacity: interleukin-8 (IL-8), C-C chemokine ligand 3 (CCL3), heat shock protein 70 kDa 1B 
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(HSPA1B), granzyme B (GZMB), and matrix metalloproteinase 8 (MMP-8)3. When combined with age, they 
yielded PERSEVERE, a highly sensitive predictor of mortality with 99% negative predictive value3. PERSEVERE 
has been tested in several cohorts and reliably estimates mortality risk among children with septic shock8–10. 
PERSEVERE-II combines platelet count with the five biomarkers to yield a mortality risk model that might have 
broader applicability across a wide range of sepsis phenotypes8.
The PERSEVERE models were developed exclusively among patients admitted to the intensive care unit (ICU) 
and meeting criteria for septic shock. It is unknown whether these models can estimate the risk of deterioration 
among non-ICU patients suspected of being bacterially infected at the time of suspicion for infection. This is 
conceptually important because risk models often perform differently when applied to cohorts that are clinically 
different than the original cohorts in which the models were derived. Here, we sought to expand the application 
of these previously validated biomarker models to a novel patient population in a non-ICU setting, and to a dif-
ferent outcome metric. Our primary aim was to determine if PERSEVERE, PERSEVERE-II, or the PERSEVERE 
biomarkers, can reliably estimate the risk of clinical deterioration within 72 hours of the initial suspicion for 
bacterial infection among immunocompromised pediatric patients. Secondarily, we determined if the models or 
biomarkers reliably estimate the risk of 28-day mortality in this population.
Study Design and Methods
Study Design. The study protocol was approved by the Institutional Review Board of Cincinnati Children’s 
Hospital Medical Center (CCHMC). This was a prospective study following a cohort of patients admitted to 
Cincinnati Children’s Hospital Medical Center (both general medical and surgical wards and intensive care units) 
between July 2016 and September 2017 with clinical suspicion for infection, defined by the acquisition of a blood 
culture at any point during the admission by the primary team, performed independently without interference 
from the research team. Upon enrollment, GZMB, HSPA1B, IL-8, CCL3, and MMP-8 levels were measured from 
blood collected at the time of concern for infection.
Patients and Data Collection. Patients were included if they were admitted to CCHMC, met at least one 
criterion within the definition of immunocompromised (Table 1), had bacterial cultures sent during admission, 
and had a residual laboratory sample (a specimen in the clinical laboratory that would otherwise be discarded) 
available that was drawn within six hours of the qualifying blood culture. Patients were excluded if they did not 
meet the definition of immunocompromised or did not have a residual laboratory sample. No age cutoffs were 
applied. A waiver of consent was granted by the institutional review board as there was no more than minimal 
risk to the subjects, and no direct subject contact. Subjects were recruited using the electronic medical record 
for the institution. If more than one residual sample was available, the one drawn temporally closest to the blood 
culture was used. Patients could be enrolled in the study more than once, depending on if more than one blood 
culture was sent during admission. Subsequent blood cultures and associated residual samples were collected at 
least 24-hours from prior samples utilized. Thus, each subject could account for more than one episode in the 
study, defined as any new concern from the primary team for infection, as evidenced by acquisition of a new 
blood culture.
Clinical and demographic data were collected using the electronic medical record. Demographic data 
included age, gender, co-morbidities, reason for immunocompromised status, physical location of the patient at 
the time of specimen collection, and whether location changed within 72 hours. Clinical data included results of 
microbiological data (blood, urine, cerebrospinal fluid, pleural, peritoneal, and respiratory cultures), complete 
blood counts, basic metabolic profiles, liver function tests, relevant radiologic testing, as well as information on 
respiratory support, need for vasoactive medications, fluid requirements, changes in neurological status, and 
survival at 28 days.
Main Outcome Measures and Primary Analysis. Our primary outcome of interest was clinical deteri-
oration within 72 hours of evaluation for possible bacterial infection. We also evaluated mortality within 28 days 
of being evaluated for possible infection as a secondary outcome measure. Clinical deterioration was defined 
as a significant change in clinical status, including transfer to an intensive care unit, severe respiratory insuffi-
ciency or respiratory failure (initiation of high flow nasal cannula, non-invasive positive pressure ventilation, 
or intubation), administration of ≥60 mL/kg (or ≥3 L if ≥50 kg) of crystalloid in a 24 hour period, initiation of 
vasopressors or inotropic agents, altered mental status, or death (Table 2). Subjects met the definition of clinical 
deterioration if they fulfilled any one of the above criteria.
The primary analysis focused on the ability of PERSEVERE and PERSEVERE-II to estimate the risk of the 
two outcomes of interest. In the event that PERSEVERE and PERSEVERE-II did not perform well, we planned, 
Neutropenia (ANC < 0.5 K/mcL)
Exposure to Chemotherapeutic Agent within prior 7 days
Exposure to Myeloablative Radiation within prior 7 days
Receipt of Solid Organ Transplant and Exposure to Immunosuppressiona within prior 7 days
Receipt of Bone Marrow Transplant and Exposure to Immunosuppressiona within prior 7 days
Table 1. Definition of Immunocompromised. aImmunosuppression includes: high dose steroids (≥2 mg/kg/
day methylprednisolone or equivalent), calcineurin inhibitor, anti-proliferative agent (i.e. mycophenolate or 
azathioprine), mTOR inhibitor (i.e. sirolimus), monoclonal antibody, thymoglobulin.
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a priori, to derive new models using the PERSEVERE biomarkers, age, and platelet count to estimate the risk of 
the two outcomes of interest.
Study Procedures. Residual samples obtained from the CCHMC clinical laboratory were used to measure 
serum protein concentrations of the five biomarkers using a multiplex magnetic bead platform (MILLIPLEX™ 
MAP) designed by the EMD Millipore Corporation (Billerica, MA), and a Luminex® 100/200 System (Luminex 
Corporation, Austin, TX).
Statistical Analysis. Data were described using medians and interquartile ranges, with individual biomarker 
performance evaluated by calculating the area under the receiver operating characteristic curves (AUROC’s). 
Comparisons between survivors and non-survivors, as well as those with and without clinical deterioration, 
were assessed using the Mann-Whitney U-test or χ-square test as appropriate. Using the previously derived 
PERSEVERE3 and PERSEVERE-II8 models, we assigned each subject a mortality probability, and thereafter cal-
culated the AUROC’s for estimating the risk of clinical deterioration and 28-day mortality. The above analyses 
were performed using SigmaPlot version 13.0 software (Systat Software, Inc. San Jose, CA, USA). New decision 
trees were derived for risk of clinical deterioration and 28-day mortality using a classification and regression tree 
(CART) analysis, and taking into account the PERSEVERE biomarkers, age, and platelet count. The models were 
built using Salford Predictive Modeler version 6.6 (Salford Systems, San Diego, CA, USA). Decision tree perfor-
mance characteristics were evaluated using the VassarStats website and are presented with their respective 95% 
confidence intervals.
Ethics statement. All experimental protocols were approved by the institutional review board at Cincinnati 
Children’s Hospital Medical Center. The methods were carried out in accordance with the guidelines and regu-
lations of said review board. As there was no direct patient contact, and no potential harm to subjects, the IRB 
granted a waiver of consent for this study.
Results
Cohort Characteristics. There were 293 subjects included in the study, yielding 400 episodes of suspected 
bacterial infection. Eighty-three subjects were enrolled more than once in the study, with 90% of enrollment 
episodes occurring at least ten days from that prior. The majority of subjects were re-enrolled after several weeks 
or months. The median age was 7.8 years (IQR 3.1–13.8 years). Fifty-three percent (n = 213) of the population 
had a primary oncologic diagnosis, 24% (n = 95) had received a bone marrow transplant, and 21% (n = 85) had 
received a solid organ transplant. Forty-eight percent (n = 193) of the cohort was neutropenic, and 48% (n = 190) 
were leukopenic. The overall infection rate was 37% (n = 148), with 70% of those patients having some form of 
culture positivity. The infection rate was highest among patients with solid organ transplants at 48%. The majority 
of subjects were in a non-ICU location at the time of suspicion for bacterial infection (n = 339), with 48 subjects 
residing in the PICU and 13 in the cardiac ICU at the time of enrollment. Among the patients initially evalu-
ated in the general hospital wards, 7% (n = 25) required transfer to an ICU within 72 hours of study enrollment. 
Eight percent (n = 30/400) of the cohort had shock, defined as requiring significant fluid resuscitation, inotropic, 
or vasopressor support. Twenty-eight day mortality for the cohort was 5%, but was significantly higher among 
patients initially evaluated in an ICU (23%) compared to patients initially evaluated in a general ward (2%) (χ² 
(2, n = 400) = 41.2, p-value < 0.001).
Clinical Deterioration. The clinical characteristics of the cohort are shown in Table 3, according to whether 
study subjects met criteria for clinical deterioration. There were no differences in median age, gender, or platelet 
count. The most common manifestations of clinical deterioration were new vasoactive requirement (27%), res-
piratory insufficiency or failure (26%), or transfer to an ICU (25%), followed by new altered mental status (13%), 
significant fluid resuscitation (11%), and death (1%). ICU patients were significantly more likely to demonstrate 
clinical deterioration with 52% deteriorating within 72 hours of enrollment compared with only 8% of non-ICU 
patients (χ² (2, n = 400) = 75.8, p-value < 0.001). Patients with a primary oncologic diagnosis or whom had 
undergone bone marrow transplant were less likely to show clinical deterioration, whereas those with solid organ 
transplants were more likely to deteriorate. Additionally, patients confirmed to have bacterial infection were 
more likely to show clinical deterioration than non-infected subjects (25% vs. 9%), and 62% of patients who 
clinically worsened were bacterially infected (χ² (2, n = 400) = 17.2, p-value < 0.001). Patients with evidence of 
clinical deterioration were significantly more likely to die within 28 days (20% mortality rate versus 3%) (χ² (2, 
n = 400) = 27.5, p-value < 0.001).
Fulfillment of Any of the following criteria:
Transfer to an ICU (if originally located in a non-ICU)
Initiation of High Flow Nasal Cannula, Non-Invasive Positive Pressure Ventilation or Invasive Positive Pressure Ventilation
Receipt of ≥60 mL/kg of crystalloid if <50 kg OR ≥3 L of crystalloid if ≥50 kg
Initiation of Inotropic of Vasopressor Support (epinephrine, norepinephrine, vasopressin, phenylephrine, milrinone, dopamine)
New Onset Altered Mental Status (significant decline in GCS, somnolence, seizure)
Death
Table 2. Definition of Clinical Deterioration within 72 Hours.
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We assigned a PERSEVERE- and PERSEVERE-II-based mortality risk to each study subject, and assessed their 
ability to identify study subjects with subsequent clinical deterioration. Neither performed well, with the AUROC 
of PERSEVERE at 0.57 (0.51–0.63, p-value 0.05), and PERSEVERE-II at 0.63 (0.57–0.69, p-value 0.0003).
We then attempted to derive a new model via classification and regression tree analysis, using the five 
PERSEVERE biomarkers, age, and platelet count as candidate predictor variables (Fig. 1). The root node included 
all 400 subjects with each subsequent daughter node arising from binary partitions of specific biomarkers. IL-8 
concentration informed the first decision point with levels >1070 pg/mL yielding a high risk terminal node (ter-
minal node 5) with 52% of subjects demonstrating clinical deterioration. The other higher risk nodes were ter-
minal nodes 2 and 4 with 22% and 24% of patients demonstrating clinical deterioration, respectively. Subjects 
allocated to terminal nodes 3 and 1 were low risk with a 2.0–3.8% rate of clinical deterioration. The AUROC 
of this new model to predict clinical deterioration was 0.81 (0.76–0.87, p-value < 0.0001), with a sensitivity of 
86% and negative predictive value of 97%. Further test characteristics can be found in Table 4. The ten-fold 
cross-validation AUC for the model was 0.72.
28-Day Mortality. The clinical characteristics of survivors and non-survivors at 28-days are displayed in 
Table 5. There were no differences between cohorts in median age, gender, primary diagnosis, or platelet count. A 
significantly higher proportion of ICU patients were deceased at 28-days: 23% versus 2% (χ² (2, n = 400) = 41.2, 
p-value < 0.001). As expected, more than 50% of non-survivors showed clinical deterioration within 72-hours of 
infectious evaluation, compared with just 13% of survivors (χ² (2, n = 400) = 27.5, p-value < 0.001).
We further evaluated the utility of the PERSEVERE and PERSEVERE-II models to predict mortality at 
28-days in this cohort of immunocompromised patients. As with clinical deterioration, the AUROC’s were low at 
0.62 (0.46–0.79, p-value 0.06), and 0.67 (0.55–0.79, p-value 0.008), respectively. We again derived a new model in 
the same manner as previously described using the five PERSEVERE biomarkers, age, and platelet counts as can-
didate predictor variables (Fig. 2). The root node included all 400 subjects, and similar to the clinical deterioration 
model, IL-8 served as the first decision point. Terminal node 5 was the highest risk node, as 24% of subjects with 
IL-8 levels >974 pg/mL died by 28-days. Terminal nodes 1, 2, and 4 were low risk nodes with mortality ranging 
from 0–5%, and terminal node 3 was higher risk with 13% mortality. The AUROC of the new model to predict 
28-day mortality was 0.87 (0.80–0.94, p-value < 0.0001). The summary ten-fold cross-validation AUC for the 
model was 0.77. The sensitivity of the model was 100%, and the negative predictive value was 100%. Further test 
characteristics can be found in Table 4.
Discussion
PERSEVERE and PERSEVERE-II are validated stratification tools to estimate baseline mortality risk among chil-
dren with septic shock. These models have been derived and tested exclusively among critically ill patients with 
septic shock. We prospectively tested these tools in a cohort of largely general ward-based, immunocompromised 
pediatric patients. As the AUROC’s of both stratification tools were too low to have clinical utility, we used the 
five PERSEVERE biomarkers to derive new highly sensitive and predictive models, yielding novel applications 
for the PERSEVERE biomarkers.
We present the first use of the PERSEVERE biomarkers to prognosticate clinical deterioration. Undoubtedly, 
understanding a patient’s mortality risk is important, but perhaps more salient to a clinician is the ability to pre-
dict trajectory within the next several days. Knowing which patients are imminently likely to worsen encourages 
vigilance and earlier intervention. It is unsurprising that the AUROC’s to predict clinical deterioration for both 
PERSEVERE and PERSEVERE-II were lower in our population. The present cohort is vastly different than those 
in prior work: these mostly non-critically ill subjects started at a different place in their infectious course, 80% 
of deteriorating patients still remained alive at 28 days, and all were immunocompromised. The original models 
speak to mortality risk, and although the outcomes are biologically related, a model to predict clinical deteriora-
tion targets a different endpoint than one predicting mortality.
This is also the first testing of PERSEVERE to predict mortality risk in a non-ICU setting, among patients with 
bacterial infection but predominantly not in shock. Of the 400 subjects, only 15% resided in an ICU at the time of 
suspicion for infection, and less than 10% were in a state of shock. We assigned each patient a PERSEVERE- and 
PERSEVERE-II- derived mortality risk and although significantly different between survivors and non-survivors, 
Stable Clinical Course 
(n = 340)
Clinical Deterioration 
(n = 60) p-value
Age (years), median (IQR) 7.9 (3.6–13.7) 7.0 (1.5–14.8) 0.51
Female, % 46% 43% 0.06
Bone Marrow Transplant or Oncologic Diagnosis, % 74% 60% 0.03
Solid Organ Transplant, % 19% 35% 0.007
Non-ICU Location, % 91% 47% <0.001
Platelet Count (K/mcL), median (IQR) 76 (33–184) 96 (38–214) 0.45
Bacterially Infected, % 33% 62% <0.001
PERSEVERE Mortality Risk, median (IQR) 0.01 (0.01–0.01) 0.01 (0.01–0.18) <0.001
PERSEVERE-II Mortality Risk, median (IQR) 0.007 (0.007–0.13) 0.09 (0.007–0.33) <0.001
28-Day Mortality, % 3% 20% <0.001
Table 3. Clinical Characteristics of Subjects with Stable Clinical Course vs. Clinical Deterioration.
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the AUROC’s for clinically-relevant prognostication were low. This could be related to several factors. Age 
(PERSEVERE) and platelet count (PERSEVERE-II) were decision points in the original models but not in the 
new mortality model. PERSEVERE-II was recalibrated incorporating platelet count, and performed particularly 
well in a subset of septic patients with thrombocytopenia-associated multiple organ failure (TAMOF)11–13. Our 
analysis showed no differences in age or platelet count between survivors and non-survivors. Age likely played 
less of a role in our model since the range was so large (2 months to 38 years). In addition, almost 50% of our 
ROOT   N = 400 
Class # Rate 
NO 341 0.853 
YES 59 0.148 
MMP8  25363 
Class # Rate 
NO 50 0.980 
YES 1 0.020 
MMP8 > 25363 
Class # Rate 
NO 19 0.760 
YES 6 0.240 
CCL3  55 
Class # Rate 
NO 70 0.778 
YES 20 0.222 
CCL3 > 55 
Class # Rate 
NO 69 0.908 
YES 7 0.092 
IL8  1070 
Class # Rate 
NO 318 0.903 
YES 34 0.097 
IL8 > 1070 
Class # Rate 
NO 23 0.479 
YES 25 0.521 
HSPA1B  
187800 
Class # Rate 
NO 179 0.962 
YES 7 0.038 
HSPA1B > 
187800 
Class # Rate 
NO 139 0.837 
YES 27 0.163 
TN2 
TN3 TN4 
TN5 
TN1 
Figure 1. New Classification and Regression Tree to Predict Clinical Deterioration. The classification tree 
consists of four biomarker-based decision rules with five terminal daughter nodes. The tree incorporates four of 
five PERSEVERE biomarkers: interleukin-8 (IL8), heat shock protein 70 kDa 1B (HSPA1B), chemokine ligand 
3 (CCL3), and matrix metalloproteinase-8 (MMP8). Each node denotes the number of subjects in the node, the 
serum concentration of a given biomarker determining the branch point (pg/mL), and both the total number 
and accompanying rate of subjects with clinical deterioration or clinical stability. Terminal Nodes 1 and 3 are 
considered low risk terminal nodes; terminal nodes 2, 4, and 5 are high risk. The AUROC for this model was 0.81.
Sensitivity Specificity PPV NPV Positive LR Negative LR
Clinical Deterioration Model 86% (74–94) 67% (62–72) 31% (24–39) 97% (93–98) 2.6 (2.2–3.2) 0.2 (0.1–0.4)
28-Day Mortality Model 100% (81–100) 69% (64–74) 15% (10–23) 100% (98–100) 3.2 (2.8–3.8) —
Table 4. Test Characteristics of the New Clinical Deterioration and New 28-Day Mortality Models. PPV 
positive predictive value, NPV negative predictive value, LR likelihood ratio.
www.nature.com/scientificreports/
6Scientific REPORTS |           (2019) 9:424  | DOI:10.1038/s41598-018-36743-z
cohort was neutropenic and leukopenic, which could affect biomarker levels, albeit in unpredictable ways. In our 
prior work in this cohort, median procalcitonin (PCT) levels were significantly higher in lymphopenic patients 
and lower in neutropenic patients. In the present study, the biomarkers that created the first three decision points 
in the CART analysis (IL-8, HSPA1B and CCL-3) were both higher (IL-8 and CCL-3) and lower (HSPA1B) in 
lymphopenic and neutropenic patients. Finally, 28-day mortality rates were quite different between our cohort 
and those in earlier work. Five percent of the current population was deceased at 28-days, with mortality in prior 
studies ranging from 10–13%3,8,9, which could have impacted the test characteristics.
Survivors to 28-
Days (n = 379)
Non-Survivors to 
28-Days (n = 21) p-value
Age (years), median (IQR) 7.9 (3.5–13.8) 5.4 (1.6–13.0) 0.21
Female, % 46% 43% 0.96
Bone Marrow Transplant or Oncologic Diagnosis, % 72% 71% 0.87
Solid Organ Transplant, % 27% 19% 0.98
Non-ICU Location, % 88% 33% <0.001
Platelet Count (K/mcL), median (IQR) 81 (33–190) 57 (46–151) 0.82
Bacterially Infected, % 36% 57% 0.08
PERSEVERE Mortality Risk, median (IQR) 0.01 (0.01–0.01) 0 (0.01–0.01) 0.005
PERSEVERE-II Mortality Risk, median (IQR) 0.007 (0.007–0.17) 0.19 (0.007–0.33) 0.005
Clinical Deterioration, % 13% 57% <0.001
Table 5. Clinical Characteristics of Survivors vs Non-Survivors.
ROOT   N = 400 
Class # Rate 
Survive
d 
379 0.948 
Death 21 0.053 
CCL3  22 
Class # Rate 
Survive
d 
35 0.946 
Death 2 0.054 
CCL3 > 22 
Class # Rate 
Survive
d 
229 1.000 
Death 0 0.000 
CCL3  62 
Class # Rate 
Survive
d 
41 0.872 
Death 6 0.128 
CCL3 > 62 
Class # Rate 
Survive
d 
33 1.000 
Death 0 0.000 
IL8  974 
Class # Rate 
Survive
d 
336 0.977 
Death 8 0.023 
IL8 > 974 
Class # Rate 
Survive
d 
41 0.759 
Death 13 0.241 
HSPA1B  
330497 
Class # Rate 
Survive
d 
264 0.992 
Death 2 0.008 
HSPA1B > 
330497 
Class # Rate 
Survive
d 
74 0.925 
Death 6 0.075 TN1 TN2 TN3 TN4 
TN5 
Figure 2. New Classification and Regression Tree to Predict 28-Day Mortality. The classification tree consists 
of four biomarker-based decision rules with five terminal daughter nodes. The tree incorporates three of five 
PERSEVERE biomarkers: interleukin-8 (IL8), heat shock protein 70 kDa 1B (HSPA1B), and chemokine ligand 
3 (CCL3). Each node denotes the number of subjects in the node, the serum concentration of a given biomarker 
determining the branch point (pg/mL), and both the total number and accompanying rate of survivors and 
non-survivors. Terminal nodes 1, 2, and 4 are low risk nodes. Terminal node 3 is higher risk, with terminal node 
5 being the highest risk node. The AUROC for this model was 0.87.
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A major strength of the study is the design. This was a prospective cohort study drawing on a relatively large 
pediatric population, which generated granular data. This work focused on a particularly vulnerable group, 
immunocompromised patients, in which infection sets in more readily, and progresses with little resistance. This 
population would benefit from reliable prognostication, perhaps more than any other sub-group, as they often 
rapidly decline. Early knowledge of expected clinical trajectory and mortality risk could inform clinical decision 
making regarding triage, resource utilization, and therapy. By evaluating clinical deterioration, we also present a 
new avenue for application of the PERSEVERE biomarkers – a different outcome metric that can provide clini-
cians insight into the expected course over the next 72 hours.
There are two significant weaknesses of this study. The first is that we employed stringent criteria to define 
immunocompromised, which could have led to the exclusion of some high-risk subjects. The second weakness is 
the under-performance of the previously validated PERSEVERE and PERSEVERE-II models. But it is important 
to remember that cohort characteristics undoubtedly impact biomarker performance. Testing these stratification 
tools in subjects who are less sick, have lower mortality rates, and are starting from different points in the course 
of infection is likely to yield disparate results. Our data suggests that the PERSEVERE biomarkers reflect common 
pathways to deterioration or death from bacterial infection, but the way in which they inform us depends on a 
given patient’s starting point.
Despite the low AUROC’s associated with the original PERSEVERE-based models, using the same biomarkers 
in different classification and regression-tree based models to predict clinical deterioration and mortality yielded 
promising results. The new tools have very low false negative rates, an important feature for stratifying tests. 
Future work is required to prospectively validate the two new models.
Conclusion
We evaluated the previously validated biomarker risk models, PERSEVERE and PERSEVERE-II, in several novel 
ways: to stratify patients based on a new outcome metric, clinical deterioration, among immunocompromised 
pediatric patients, and in a non-ICU setting. Although the original models had low AUROC’s to prognosticate 
about clinical deterioration and mortality, we were able to derive new highly sensitive and predictive models 
using the same variables in different regression patterns. This work represents an important step toward identify-
ing at-risk infected pediatric patients whom require a heightened state of vigilance.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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